PARP1 and pancreatic neoplasm: PARP inhibitors (olaparib, niraparib, rucaparib and talazoparib) are currently approved as a monotherapy by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for breast, ovarian, fallopian, primary peritoneal, prostate and pancreatic cancer.